Evidence map›Paper›PMID 24837543›Full record

Trial reportContemporary clinical trials2014

A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]).

J Kellogg Parsons, John P Pierce, James Mohler, Electra Paskett, Sin-Ho Jung, Peter Humphrey, John R Taylor, Vicky A Newman, Leslie Barbier, Cheryl L Rock and 1 more

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Contemporary clinical trials, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Prostate cancer and subsequent nutritional outcomes: the role of diagnosis and treatment.Journal of cancer survivorship : research and practice · 2019
    Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

J Kellogg ParsonsDivision of Urologic Oncology, UC San Diego Moores Cancer Center, La Jolla, CA, United States; Department of Urology, UC San Diego Health System, La Jolla, CA, United States; VA San Diego Healthcare System, La Jolla, CA, United States. Electronic address: jkparsons@ucsd.edu.
John P PierceDepartment of Family and Preventive Medicine, University of California, San Diego School of Medicine, La Jolla, CA, United States.
James MohlerDepartment of Urology, Roswell Park Cancer Institute, Buffalo, NY, United States.
Electra PaskettDepartment of Medicine, College of Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, OH, United States.
Sin-Ho JungAlliance Statistics and Data Center, Duke University Medical Center, Durham, NC, United States.
Peter HumphreyDepartment of Pathology, Washington University Medical School, St. Louis, MO, United States.
John R TaylorAlliance Central Protocol Operations, University of Chicago, Chicago, IL, United States.
Vicky A NewmanDepartment of Family and Preventive Medicine, University of California, San Diego School of Medicine, La Jolla, CA, United States.
Leslie BarbierDepartment of Family and Preventive Medicine, University of California, San Diego School of Medicine, La Jolla, CA, United States.
Cheryl L RockDepartment of Family and Preventive Medicine, University of California, San Diego School of Medicine, La Jolla, CA, United States.
James MarshallDepartment of Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, United States.
University of California, San Diego · USRoswell Park Comprehensive Cancer Center · USDuke Medical Center · USIndo-American Center · USThe Ohio State University · USUC San Diego Health System · USWashington University in St. Louis · US

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
CANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4M
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
CANCER &LEUKEMIA GROUP B STATISTICAL CENTERU10CA033601 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SARGENT, DANIEL J. · 1985 to 2013
$69.4M
Diet change among prostate cancer patients under expectant managementR01CA132951 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARSHALL, JAMES · 2009 to 2015
$2.4M
NCI NIH HHS 1R01 CA132951-01A1NCI NIH HHS CA31946NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA132951NCI NIH HHS U10 CA031946NCI NIH HHS U10 CA033601NCI NIH HHS U10 CA180821
6 · The paper itself

Abstract

backgroundDiet may substantially alter prostate cancer initiation and progression. However, large-scale clinical trials of diet modification have yet to be performed for prostate cancer. The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]) is investigating the effect of increased vegetable consumption on clinical progression in men with localized prostate cancer. STUDY

designMEAL is a randomized, phase III clinical trial designed to test whether an intervention that increases vegetable intake will decrease the incidence of clinical progression in men with clinically localized prostate cancer on active surveillance. We are randomizing 464 patients to either a validated telephone-based diet counseling intervention or a control condition in which patients receive a published diet guideline. The intervention will continue for two years. The primary outcome variable is clinical progression defined by serum prostate-specific antigen (PSA) and pathological findings on follow-up prostate biopsy. Secondary outcome variables include incidence of surgical and non-surgical treatments for prostate cancer, prostate-cancer related patient anxiety and health-related quality of life.

conclusionThe MEAL Study is assessing the effectiveness of a high-vegetable diet intervention for preventing clinical progression in men with localized prostate cancer on active surveillance.

Indexed as

Research DesignVegetablesAgedAged, 80 and overCounselingDiet TherapyDisease ProgressionHumansMaleMiddle AgedProstate-Specific AntigenProstatic NeoplasmsQuality of LifeTelephoneProstate-Specific AntigenActive surveillanceCarotenoidsDietNutritionOutcomesProstate cancer

Identifiers

PMID24837543
PMCPMC4280832
OpenAlexW2002839083

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.